Incidence of and risk factors associated with lung metastases in newly diagnosed epithelial ovarian cancer with a look on prognosis after diagnosis: a population-based cohort study of the SEER database

被引：8
作者：
Xu, Jiaqin [1 ]
Hussain, Iftikhar [1 ]
Wang, Liuying [1 ]
Deng, Kui [1 ]
Zhao, Liang [1 ]
Zhou, Keqiang [1 ]
Zhang, Liuchao [1 ]
Xu, Zhengyi [1 ]
Li, Kang [1 ]
机构：
[1] Harbin Med Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Harbin 150086, Heilongjiang, Peoples R China
来源：
ARCHIVES OF GYNECOLOGY AND OBSTETRICS | 2021年 / 304卷 / 04期
基金：
中国国家自然科学基金;
关键词：
Epithelial ovarian cancer; Lung metastases; SEER; Incidence; Risk factors; Prognosis;
D O I：
10.1007/s00404-021-05997-w
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
Purpose Patients with lung metastases (LM) from epithelial ovarian cancer (EOC) (EOCLM) usually have a poor prognosis. However, there is no consensus on the optimal management of these patients. In this study, we aimed to take a look at the incidence of LM and factors associated with its occurrence as well as the prognosis in newly diagnosed EOC with LM on a population level. Methods EOC patients diagnosed between the years 2010 and 2016 were identified from the Surveillance, Epidemiology, and End Results (SEER) program database. Multivariable logistic regression and multivariable Cox regression were used to investigate the factors that could predict the occurrence of and prognosis after diagnosis of EOC with LM. Results Of the 33,418 qualified EOC patients, 2240 (6.7%) were noted to have LMs at the time of EOC diagnosis. Higher T stage, N1 stage, advanced tumor grade, and elevated cancer antigen-125 levels were found to be associated with a higher risk of having LM at the time of EOC diagnosis. The median survival time after diagnosis with EOCLM was found to be 13.0 months (interquartile range: 3.0-34.0 months). Being unmarried and having mucinous histology were both associated with increased all-cause death risk from EOCLM. However, the primary tumor originated from the midline of ovaries, surgical management, and whether patient received chemotherapy or not predicted improved overall survival. The median survival time of patients was significantly longer for EOCLM cases managed surgically (31.0 months) versus those who did not have surgery (4.0 months), as well as EOCLM cases received chemotherapy (23.0 months) versus those who did not have chemotherapy (2.0 months). Conclusion This retrospective cohort study showed that de novo LM was infrequent in EOC patients overall and when present predicted poor prognosis. The findings can be potentially useful in formulating for follow-up strategies, screening tools, and personalized interventions.
引用
收藏
页码：1007 / 1020
页数：14
相关论文
共 32 条
  • [1] Siegel R.L., Miller K.D., Jemal A., Cancer statistics, 2020, CA Cancer J Clin, 70, 1, pp. 7-30, (2020)
  • [2] Howlader N., Ries L.A., Mariotto A.B., Reichman M.E., Ruhl J., Cronin K.A., Improved estimates of cancer-specific survival rates from population-based data, J Natl Cancer Inst, 102, 20, pp. 1584-1598, (2010)
  • [3] Cancer Stat Facts: Ovarian Cancer. Surveillance, Epidemiology, and End Results Program
  • [4] Rose P.G., Piver M.S., Tsukada Y., Lau T.S., Metastatic patterns in histologic variants of ovarian cancer. An autopsy study, Cancer, 64, 7, pp. 1508-1513, (1989)
  • [5] Jelovac D., Armstrong D.K., Recent progress in the diagnosis and treatment of ovarian cancer, CA Cancer J Clin, 61, 3, pp. 183-203, (2011)
  • [6] Deng K., Yang C., Tan Q., Song W., Lu M., Zhao W., Lou G., Li Z., Li K., Hou Y., Sites of distant metastases and overall survival in ovarian cancer: a study of 1481 patients, Gynecol Oncol, 150, 3, pp. 460-465, (2018)
  • [7] Lutz S., Norrell R., Bertucio C., Kachnic L., Johnson C., Arthur D., Schwarz M., Palardy G., Symptom frequency and severity in patients with metastatic or locally recurrent lung cancer: a prospective study using the Lung Cancer Symptom Scale in a community hospital, J Palliative Med, 4, 2, pp. 157-165, (2001)
  • [8] Procaccio L., Bergamo F., Manai C., Di Antonio V., Fassan M., Zagonel V., Lonardi S., Loupakis F., An overview on clinical, pathological and molecular features of lung metastases from colorectal cancer, Expert Rev Respir Med, 13, 7, pp. 635-644, (2019)
  • [9] Kerr V.E., Cadman E., Pulmonary metastases in ovarian cancer, Analysis of 357 Patients. Cancer, 56, 5, pp. 1209-1213, (1985)
  • [10] Keskin S., Kucucuk S., Ak N., Atalar B., Sari M., Sozen H., Ibis K., Topuz S., Saip P., Survival impact of optimal surgical cytoreduction in recurrent epithelial ovarian cancer with brain metastasis, Oncol Res Treat, 42, 3, pp. 101-106, (2019)
1234